Results 101 to 110 of about 43,621 (186)

Dual Action of Dipyridamole in Experimental Rheumatoid Arthritis: Suppression of Joint Inflammation and Upregulation of Muscle Anabolism via Adenosine and AMPK Pathways

Arthritis &Rheumatology, Volume 78, Issue 7, Page 1535-1553, July 2026.
Objective Rheumatoid sarcopenia, characterized by the progressive loss of skeletal muscle mass and function, is a frequent comorbidity in rheumatoid arthritis (RA), linked to prolonged, severe systemic inflammation. Purinergic signaling (adenosine, AMP, and ATP) plays a crucial role in inflammation, myogenesis, and muscle hypertrophy.
Miguel Marco‐Bonilla, Maria Fresnadillo, Irene Sanchez‐Platero, Macarena de la Riva‐Bueno, Fernando Huete‐Toral, Gonzalo Carracedo, Carmen Conde, Yolanda Benitez, Pablo Minguez, Sandra Carolina Cifuentes, Joaquin Rams, Gabriel Herrero‐Beaumont, Raquel Largo, Aránzazu Mediero   +13 more
wiley   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 66-80, July 2026.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo, Sarah N. Hilmer, David J. Hunter, Stephanie Mathieson, Riyaas Mohamed, Leo Li, Natalie Fung, Anthony Yue, Manuela L. Ferreira   +8 more
wiley   +1 more source

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 109-113, July 2026.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi, Andrea Pasta, Walter Elisei, Brigida Barberio, Giammarco Mocci, Giovanni Maconi, Antonietta Gerarda Gravina, Raffaele Pellegrino, Giorgia Bodini, Edoardo Vincenzo Savarino, Alfredo Papa, Italian Network for Inflammatory Bowel Diseases (IN‐IBD), Davide G. Ribaldone, Antonio Ferronato, Greta Lorenzon, Davide Checchin, Francesca Lambroglia, Francesco Ferrara, Carla Felice, Giovanni Cataletti, Giorgia Bodini, Andrea Pasta, Giovanni Aragona, Patrizia Perazzo, Federica Gaiani, Stefano Kayali, Fabio Cortellini, Francesco Costa, Lorenzo Bertani, Antonella Scarcelli, Mariaelena Serio, Emanuele Bendia, Laura Bolognini, Daniele Balducci, Claudia Quatraccioni, Francesco Martini, Michele Montori, Simona Piergallini, Francesca Maria Onidi, Paolo Usai Satta, Giorgia Orrù, Raffaele Colucci, Francesco Bachetti, Gabrio Bassotti, Elisabetta Antonelli, Costantino Zampaletta, Giulia Rocco, Carlotta Sacchi, Franco Scaldaferri, Daniele Napolitano, Roberto Faggiani, Michela Di Fonzo, Rita Monterubbianesi, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Roberta Pica, Maddalena Zippi, Andrea Cocco, Claudio Cassieri, Roberto Lorenzetti, Gian Marco Giorgetti, Valeria Clemente, Patrizio Scarozza, Girolamo Bevevino, Giulia Zerboni, Federico Iacopini, Giacomo Forti, Laurino Grossi, Serafina Fiorella, Giovanni Lombardi, Marta Patturelli, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Pietro Capone, Guido Daniele Villani, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Giuseppe Pranzo, Paolo Tonti, Viviana Neve, Libera Fanigliulo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Manuela Marzo, Ileana Luppino, Francesco Luzza, Rocco Spagnuolo, Stefano Rodinò, Ladislava Sebkova, Antonio De Medici, Domenico Catarella, Dario D’Agostino, Elisabetta Di Bartolo   +100 more
wiley   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Treatment Outcomes of Hospitalized Patients With Inflammatory Bowel Disease at a Tertiary Care Center in Nepal: A Cross‐Sectional Study

JCC Plus, Volume 1, Issue 4, July 2026.
Overall, patients with IBD constituted 1.6% (n = 37) of all admissions to the gastroenterology ward for any indication. Most (2/3rd) hospitalized patients with IBD responded to conventional therapy; one third required advanced therapy or surgery. In‐hospital mortality was high at 5%, probably related to delayed diagnosis, limited access to advanced ...
Ajay Kumar Yadav, Bhupendra Kumar Basnet, Ramila Shrestha, Ajit Khanal, Milan Shrestha, Mukesh Sharma Poudel   +5 more
wiley   +1 more source

JAK Inhibition in PNPT1‐Related Mitochondrial Interferonopathy: A Case Report and Review of Mitochondrial–Immune Crosstalk

JIMD Reports, Volume 67, Issue 4, July 2026.
ABSTRACT Biallelic pathogenic variants in PNPT1 cause combined oxidative phosphorylation deficiency 13 (COXPD13) (MIM #614932), linking mitochondrial dysfunction to type I interferon (IFN) activation through cytosolic leakage of mitochondrial double‐stranded RNA (mt‐dsRNA).
Dan Ross Brooks, Hyun Yong Koh, Taylor Martin Kerrins, Steven Lang, Emily Bland, Rui Yang, Sarah Kogan Nicholas, Stephanie Jean Sikkink, Stephen Kralik, Christine Eng, Chaya Nautiyal Murali, Seema Lalani, Pilar Lenglet Magoulas, Lisa Emrick, Kristen Sydney Fisher, Fernando Scaglia   +15 more
wiley   +1 more source

2024 Update of the Asia‐Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management

International Journal of Rheumatic Diseases, Volume 29, Issue 7, July 2026.
ABSTRACT Aim To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier ...
Kunihiro Yamaoka, Zhanguo Li, Khin Thin Zar Myo Aung, Paul Bird, Manisha Bhochhibhoya, Minhaj Rahim Choudhury, Debashish Danda, Tsolmon Darisuren, Rudy Hidayat, Nguyen Van Hung, Yuko Kaneko, Wanruchada Katchamart, Manjari Lahiri, Chin Teck Ng, Babur Salim, Keshav Raj Sigdel, Shereen Ch'ng Suyin, Tsutomu Takeuchi, Galymzhan Togizbayev, Evan Vista, Sandini Wijeweera, Chuanhui Xu, Chak Sing Lau   +22 more
wiley   +1 more source

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease

Journal of Gastroenterology and Hepatology, Volume 41, Issue 7, Page 2006-2029, July 2026.
ABSTRACT Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab ...
Choon Jin Ooi, Khoon Lin Ling, Julajak Limsrivilai, Shu‐Chen Wei, Joyce Wing Yan Mak, Taku Kobayashi, Luan Minh Dang, Rupert W. Leong, Huiyu Lin, Meng‐Tzu Weng, Wan Chee Ong, Vineet Ahuja, Satimai Aniwan, Ryota Hokari, Wei Jie Jonathan Lee, Alex Hwong‐Ruey Leow, Wai‐Keung Leung, Wee‐Chian Lim, Govind Makharia, Katsuyoshi Matsuoka, Nazri Mustaffa, Siew‐Chien Ng, Mathew Philip, Pises Pisespongsa, Raja Affendi Raja Ali, Zhi Hua Ran, Marcellus Simadibrata, Jose Sollano, Malcolm Tan, Hang Dao Viet, Nik Razima Wan Ibrahim, Kai Chun Wu, Byong Duk Ye, Ida Hilmi, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD)   +34 more
wiley   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna, Jiezhun Gu, Yi‐Ju Li, Huiman Barnhart, Dina Halegoua‐DeMarzio, Herbert L. Bonkovsky, A. Sidney Barritt, Jean P. Molleston, Naga P. Chalasani, Marwan Ghabril   +9 more
wiley   +1 more source

Tofacitinib: New drug in the therapeutic armamentarium in ocular inflammation. [PDF]

Indian J Ophthalmol
Babu K, Mooss V.
europepmc   +1 more source